Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) Market Outlook
Thelansis’s “Advanced or Metastatic
Non-Small-Cell Lung Cancer (NSCLC) Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2024 To 2034" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Advanced
or Metastatic Non-Small-Cell Lung Cancer (NSCLC) treatment modalities options
for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and
China).
Advanced or Metastatic Non-Small-Cell
Lung Cancer (NSCLC) Overview
Lung
cancer remains the predominant cause of cancer-related mortality globally among
both males and females. The majority of lung cancer cases are classified as
non-small cell lung cancer (NSCLC), accounting for approximately 85% of cases.
The most prevalent histological subtypes within NSCLC include adenocarcinoma
(AC), squamous cell carcinoma (SCC), and large cell neuroendocrine carcinoma
(LCNEC). Advanced NSCLC, also referred to as metastatic NSCLC, is characterized
by the spread of the cancer from the lungs to other parts of the body,
rendering it incurable. In the United States, NSCLC represents the most common
form of lung cancer and frequently metastasizes to the bones, brain, liver,
skin, lymph nodes, or adrenal glands. However, it can disseminate to any region
of the body.
Geography coverage:
G8 (United States, EU5 [France,
Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust
research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal
articles, third-party research databases)
Deliverables format and
updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated
dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant
support
*As per Thelansis’s policy, we
ensure that we include all the recent updates before releasing the report
content and market model.
Salient features of Market
Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market forecasts validated
through the top-down sales methodology
- Covers clinically and commercially-relevant patient
populations/ line of therapies
- Annualized drug-level sales and patient share
projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management
strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of
incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and
patient share?
- Which events will have the greatest impact on the
market’s trajectory?
- What insights do interviewed experts provide on
current and emerging treatments?
- Which pipeline products show the most promise, and
what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for
target profiles?
- What key regulatory and payer requirements must be
met to secure drug approval and favorable market access?
- and more…
Comments
Post a Comment